Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, Yesterday

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 2 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Single weekly PTENS sessions useful in treating paediatric overactive bladder

09 Jan 2017

Single weekly sessions of parasacral transcutaneous electrical neural stimulation (PTENS) show potential in the treatment of paediatric overactive bladder (OAB), producing improvements in urinary urgency and enuresis, a study has shown.

PTENS was initially used as an alternative treatment approach to detrusor overactivity in children. However, treatment protocols requiring several sessions per week or long-lasting sessions posed a challenge to treatment adherence.

Researchers then investigated whether PTENS in single weekly sessions would be effective for paediatric OAB. A total of 16 children were randomly assigned to the EG arm (urotherapy and PTENS) or the CG arm (urotherapy and placebo electrical stimulation). Therapy was delivered in 20 weekly sessions, with each session lasting for 20 minutes. Placebo electrical stimulation was applied in the scapular area.

The children were assessed prior to treatment (T1), upon completion of the 20 sessions (T2), and 60 days after treatment completion (T3). A 3-day voiding diary, visual analogue scale (VAS), Rome III diagnostic criteria and the Bristol Scale were used in the assessments.

At T1, 100 percent had urgency and incontinence. In the EG arm, 87.5 percent had enuresis, and 50 percent had constipation. The respective rates in the CG arm were 75 and 50 percent.

Volumetric measurements made in the voiding diary, urinary frequency and constipation (as evaluated using the Rome III criteria and the Bristol Scale) were comparable between the two treatment arms.

At T3 however, the EG group showed a significant improvement in urgency, as well as an increase in dry nights in children presenting with enuresis, compared with the CG (p=0.03 for both). No difference was observed for urinary incontinence.

At both T2 and T3, the health professionals managing children who received EG perceived greater improvements in symptoms as measured by the VAS (p=0.05 and p=0.04, respectively).

The findings indicate that once-a-week sessions of PTENS are effective in the treatment of symptoms of urinary urgency and enuresis in children with OAB.

Additional studies with larger cohorts should be conducted in order to validate the present data.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, Yesterday

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 2 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.